YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[Ozempic Insulin injection pen] CR/iStock via Getty Images INVESTORS SHOULD KNOW: The obesity drug market is undergoing a structural shift, moving beyond the initial injectable GLP-1 franchise. Now, the industry is moving toward a broader…
During the lightning round of the September 10 episode of Mad Money, a caller asked if Kailera Therapeutics, Inc. (NASDAQ:KLRA) is a buy, sell, or hold. In response, Jim Cramer said: Okay, I actually know this, but okay, here's the problem…
Quick Read KLRA trades 29% below its IPO high but holds $1.17 billion in cash and carries a $42 analyst consensus price target. Merck's looming Keytruda revenue cliff and Novo Nordisk's need to defend Wegovy dominance make both natural buy…
Key Points Novo Nordisk and Kailera Therapeutics have attractive GLP-1 pipelines. Both could cash in as demand for GLP-1 drugs soars over the medium term. 10 stocks we like better than Novo Nordisk › The GLP-1 market is currently one of th…
Kailera Therapeutics Inc. (NASDAQ:KLRA) is one of the best IPO stocks with huge upside potential. On July 7, Kailera Therapeutics announced positive topline results from two Phase 3 clinical trials conducted by Hengrui Pharma for HRS-7535/…
(Updates with the latest stock movement in the first paragraph and headline.) Kailera Therapeutic PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news…
[IPO Initial Public Offering on Financial Stock Market Chart 3D render] gonin Kalohexis, a clinical-stage biotech developing a series of peptide therapies for conditions including obesity, announced on Tuesday that it has confidentially fi…
Eli Lilly shares hit a record high Tuesday after IPO stock Kailera Therapeutics posted lackluster test results for its weight-loss pill. Continue Reading
[Red dollar sign pointing down with arrow, concept of financial loss, market decline and recession, 3d render] Shares of Kailera Therapeutics (KLRA [https://seekingalpha.com/symbol/KLRA]) slipped more than 10% on Tuesday after the Waltham,…
Kailera Therapeutics (KLRA) said Tuesday that a phase 3 trial in China of its investigational oral s PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Kailera Therapeutics, Inc. In Phase 3 trial in obesity/overweight in China, HRS-7535 achieved a mean weight loss of up to 10.9% at Week 44 and a mean weight loss of up to 11.1% at Week 50 Kailera currently conducting global Phase 2 trial o…
Pfizer's (NYSE: PFE) shares have significantly underperformed broader equities over the past three years. The company's reliance on its coronavirus portfolio has been a weakness, as vaccination rates have declined, while U.S. regulators ha…
June 18 (Reuters) - Kardigan's shares rose 1.6% in their Nasdaq debut on Thursday, after the heart drug developer raised $400 million in an upsized U.S. initial public offering. The Princeton, New Jersey-based company's shares opened at…
Wall Street traded higher on Friday as investors focused on the highly anticipated public debut of SpaceX, with enthusiasm surrounding the offering helping support gains across major U.S. equity indexes. The blue-chip Dow Jones Industrial…
This year is turning out to be a massive one for initial public offerings, with Cerebras Systems delivering the biggest so far and SpaceX on track to launch the largest ever. On top of that, Anthropic and OpenAI recently filed confidential…
Key Points Parabilis and another recent IPO stock each raised more than Moderna -- which had previously been the biggest biotech IPO. Parabilis’ technology could be a game changer and potentially used across treatment areas.These 10 stocks…
Parabilis Medicines (PBLS) had a thunderous debut on Nasdaq this week — opening at a little over $33, up an exciting 67% versus the $20 initial public offering (IPO) price. PBLS raised some $670 million through the IPO, the largest haul ev…
[Wooden blocks with the word IPO and virtual stock graph. Initial Public Offering or stock launch concept.] fadfebrian Parabilis Medicines (PBLS [https://seekingalpha.com/symbol/PBLS]) climbed more than 45% in its first trading session on…
Kailera Therapeutics, Inc. Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight Addi…
In the biotech sector, private companies are moving from the sidelines into the spotlight through initial public offerings (IPOs). One of the most recent is Kailera Therapeutics(NASDAQ: KLRA), a potential competitor to Eli Lilly and Novo N…
On Tuesday, William Blair initiated coverage on Kailera Therapeutics Inc.(NASDAQ:KLRA), the latest entrant in the fast-growing weight-loss drug market. The obesity-focused biotech raised more than $600 million in April through an initial p…
Analysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment. Continue Reading
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Kailera Therapeutics (NasdaqGS:KLRA) completed its initial public o…
On April 20, 2026, RTW Investments, a 10% Owner of Kailera Therapeutics(NASDAQ:KLRA), reported the acquisition of 500,000 shares of common stock at $16.00 per share, according to the SEC Form 4 filing. The firm also received 10.28 million…
Kailera Therapeutics (KLRA) priced 39.06M shares at $16.00. The deal size was increased to 39.06M shares from 33.3M and priced at the high end of the $14.00-$16.00 range. JPMorgan, Jefferies, Leerink, TD Cowen and Evercore ISI are acting a…
Obesity biotech Kailera Therapeutics has set its sights on the US public market through an upsized $625m IPO, marking one of the largest public offerings in the sector’s history. In a 16 April statement, Kailera announced it’d be offering…
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the pricing of its…
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Kailera Therapeutics, a high-profile drug startup aiming to compete with Novo Nordisk and Eli…
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Obesity drugmaker Kailera Therapeutics plans to test investor appetites for another biotechno…
[IPO Ahead Financial Growth] narvo vexar Weight loss drug developer Kailera Therapeutics (KLRA [https://seekingalpha.com/symbol/KLRA]) and Alamar Biosciences (ALMR [https://seekingalpha.com/symbol/ALMR]), a commercial-stage proteomics comp…
March 27 (Reuters) - Kailera Therapeutics filed for a U.S. initial public offering on Friday, becoming the latest biotech company looking to tap investor appetite as listings in the space gather momentum. U.S. companies have pushed on w…
NEW YORK, Aug. 18, 2025 /PRNewswire/ -- Payoneer (NASDAQ: PAYO), the global financial technology company powering business growth across borders, today announced a strategic partnership with programmable financial services company Stripe.…